Tags : Clovis Oncology

Weekly Snapshot

PharmaShots Weekly Snapshot (September 23– 27, 2019)

1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 Trial, Patients, Previously, Treated, Advanced, Cholangiocarcinoma 2.Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis Published: Sept 27, 2019 […]Read More


Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for

Shots: 3BP to receive $12M up front, R&D milestones, an additional potential milestone with royalties on sales. Clovis to get rights to develop peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein alpha and will conduct global clinical studies excluding EU (inclusive of Russia, Turkey, and Israel) where 3BP retains rights Additionally, the […]Read More